Repro Med Systems Inc (REPR)

[budge]

new management may be a major plus here. but we can't ignore the fact that every drug regimen that is approved by the FDA for infusion opens increasing markets for REPR. they have made note of the purchases by drug companies for the purposes of trials in this area. HALO's ability to create infusible formulations out of regimens that require injection is being tested in an increasing number of trials. I would expect to see a rapidly increasing addressable market for REPR. it seems logical that others see that as well. REPR may well become a takeover or a take private target. I wouldn't like either.